Tb Trials Consortium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tb trials consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tb Trials Consortium Today - Breaking & Trending Today

Shorter treatment regimen found to be effective for treating TB

Tuberculosis (TB) is a deadly infection that occurs in every part of the world. The standard treatment for TB, a six-month multidrug regimen, has not changed in more than 40 years. Patients can find it difficult to complete the lengthy regimen, making it more likely that treatment resistance will develop. ....

Susan Dorman , Emily Henderson , Centers For Disease , University Of South Carolina , National Institutes Of Health , World Health Organization , Tb Trials Consortium , Drug Administration , College Of Medicine , Medical University , South Carolina , New England Journal , Disease Control , National Institutes , Public Health , சூசன் டோர்மன் , எமிலி ஹென்டர்சன் , மையங்கள் க்கு நோய் , பல்கலைக்கழகம் ஆஃப் தெற்கு கரோலினா , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , கல்லூரி ஆஃப் மருந்து , மருத்துவ பல்கலைக்கழகம் , தெற்கு கரோலினா , புதியது இங்கிலாந்து இதழ் , நோய் கட்டுப்பாடு ,

Path of least resistance: a novel tuberculosis regimen shortens treatment course for patients

Date Time
Path of least resistance: a novel tuberculosis regimen shortens treatment course for patients
Tuberculosis (TB) is a deadly infection that occurs in every part of the world. The standard treatment for TB, a six-month multidrug regimen, has not changed in more than 40 years. Patients can find it difficult to complete the lengthy regimen, making it more likely that treatment resistance will develop.
A multi-institutional research team led by MUSC investigator Susan Dorman, M.D., reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence. Dorman is a professor in the College of Medicine at MUSC. ....

Susan Dorman , Centers For Disease , National Institutes Of Health , Clinical Trials Group , World Health Organization , Tb Trials Consortium , Drug Administration , College Of Medicine , New England Journal , Disease Control , National Institutes , Medical University Of South Carolina , World Health Organization , Clinical Trials , Public Health , Immune Cells , சூசன் டோர்மன் , மையங்கள் க்கு நோய் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , மருத்துவ சோதனைகள் குழு , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , கல்லூரி ஆஃப் மருந்து , புதியது இங்கிலாந்து இதழ் , நோய் கட்டுப்பாடு , தேசிய நிறுவனங்கள் ,

A novel tuberculosis regimen shortens treatment course for patients

A phase III clinical trial led by an investigator at the Medical University of South Carolina found that a novel four-month regimen was just as effective at treating tuberculosis as the standard six-month regimen. The findings are reported in the May 6, 2021 New England Journal of Medicine. ....

South Carolina , United States , University Of South Carolina , Susan Dorman , Centers For Disease , National Institutes Of Health , World Health Organization , Tb Trials Consortium , Drug Administration , Health Professions , Health The No , College Of Medicine , Medical University , New England Journal , Disease Control , National Institutes , Dental Medicine , Graduate Studies , World Report , Medicine Health , Aids Hiv , Clinical Trials , Infectious Emerging Diseases , Pulmonary Respiratory Medicine , Public Health , Developing Countries ,